Cargando…

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma

BACKGROUND: Tumor cell proliferation is a predictor of survival in cutaneous melanoma. The aim of the present study was to evaluate the prognostic impact of mitotic count, Ki-67 expression and novel proliferation markers phosphohistone H3 (PHH3), minichromosome maintenance protein 4 (MCM4) and mitos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ladstein, Rita G, Bachmann, Ingeborg M, Straume, Oddbjørn, Akslen, Lars A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868809/ https://www.ncbi.nlm.nih.gov/pubmed/20398247 http://dx.doi.org/10.1186/1471-2407-10-140

Ejemplares similares

Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas - an immunohistochemical study
por: Habberstad, Andreas H, et al.
Publicado: (2011)

Tumor necrosis is associated with increased alpha(v)beta(3 )integrin expression and poor prognosis in nodular cutaneous melanomas
por: Bachmann, Ingeborg M, et al.
Publicado: (2008)

Evaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer
por: Aziz, Sura, et al.
Publicado: (2016)

The prognostic importance of PD-L1, PTEN, PHH3, and KI-67 expressions in invasive breast carcinoma
por: Imamoglu, Eda Hilal, et al.
Publicado: (2022)

PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors
por: Shin, Yooju, et al.
Publicado: (2015)

A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms
por: Qi, Gaoxiu, et al.
Publicado: (2023)

Immunoexpression of Ki-67, MCM2, and MCM3 in Ameloblastoma and Ameloblastic Carcinoma and Their Correlations with Clinical and Histopathological Patterns
por: Carreón-Burciaga, Ramón Gil, et al.
Publicado: (2015)

A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms
por: Khan, M S, et al.
Publicado: (2013)

MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers
por: Sadeghian, Dorsay, et al.
Publicado: (2022)

Utility of PHH3 in Evaluation of Mitotic Index in Breast Carcinoma and Impact on Tumor Grade
por: Mirzaiian, Elham, et al.
Publicado: (2020)

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot
por: Beelen, Karin, et al.
Publicado: (2018)

Ki-67 acts as a biological surfactant to disperse mitotic chromosomes
por: Cuylen, Sara, et al.
Publicado: (2016)

Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer
por: Yang, Jun, et al.
Publicado: (2006)

Ki-67 and MCM-2 in Dental Follicle and Odontogenic Cysts: The Effects of Inflammation on Proliferative Markers
por: Güler, Nurhan, et al.
Publicado: (2012)

Evaluation of the Ki-67 and MCM3 Expression in Cytologic Smear of Oral Squamous Cell Carcinoma
por: Rezazadeh, Fahimeh, et al.
Publicado: (2017)

Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study
por: Schuster, Cornelia, et al.
Publicado: (2016)

β2‐adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma
por: Schuster, Cornelia, et al.
Publicado: (2023)

A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis
por: Fuchs, Talia L., et al.
Publicado: (2020)

Irisin Association with Ki-67, MCM3 and MT-I/II in Squamous Cell Carcinomas of the Larynx
por: Pinkowska, Agnieszka, et al.
Publicado: (2021)

Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma
por: Hugdahl, Emilia, et al.
Publicado: (2019)

Improving mitotic cell counting accuracy and efficiency using phosphohistone‐H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading
por: Ibrahim, Asmaa, et al.
Publicado: (2022)

MCM - 2 and Ki - 67 as proliferation markers in renal cell carcinoma: A quantitative and semi - quantitative analysis
por: Mehdi, Muhammad Zain, et al.
Publicado: (2016)

MCM-2, Ki-67, and EGFR downregulated expression levels in advanced stage laryngeal squamous cell carcinoma
por: Vivatvakin, Sarocha, et al.
Publicado: (2021)

Ki-67 is a PP1-interacting protein that organises the mitotic chromosome periphery
por: Booth, Daniel G, et al.
Publicado: (2014)

Robust linear regression model of Ki-67 for mitotic rate in gastrointestinal stromal tumors
por: KEMMERLING, RALF, et al.
Publicado: (2014)

Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy
por: Schuster, Cornelia, et al.
Publicado: (2018)

HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?
por: Seo, Mikyung Kelly, et al.
Publicado: (2020)

Assessment of Ki67 in Breast Cancer: A Comparison Between the Eye-10 Method, Stepwise Counting Strategy, and International System of Ki67 Evaluation
por: Kadivar, Maryam, et al.
Publicado: (2020)

The Ki-67 and RepoMan mitotic phosphatases assemble via an identical, yet novel mechanism
por: Kumar, Ganesan Senthil, et al.
Publicado: (2016)

Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas
por: Torres-Rendon, A, et al.
Publicado: (2009)

Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas
por: Duregon, Eleonora, et al.
Publicado: (2016)

Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes?
por: Oddó, David, et al.
Publicado: (2018)

Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value
por: Joshi, Shalaka, et al.
Publicado: (2015)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki-67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions(,)
por: Choy, Bonnie, et al.
Publicado: (2016)

To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer
por: Wang, Yi-xing, et al.
Publicado: (2019)

Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
por: Fluge, Ø, et al.
Publicado: (2009)

Corrigendum: To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

Lymphatic vessel density and prognosis in cutaneous melanoma
por: Straume, O, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_0ed8cd25i331tpr9ijbgo8u4j2